Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vandetanib + anastrozole
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vandetanib + anastrozole is a combination therapy investigated for the neoadjuvant treatment of postmenopausal patients with Stage I-III hormone receptor-positive (HR+) breast cancer. Vandetanib is an oral small molecule tyrosine kinase inhibitor that dual-targets vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), aiming to inhibit angiogenesis and tumor cell proliferation. Anastrozole is a non-steroidal aromatase inhibitor that reduces circulating estrogen levels, a key driver in HR+ breast cancer. The combination was studied in a Phase 2 trial led by Stanford University (NCT00481845) to evaluate if blocking multiple signaling pathways could overcome resistance to endocrine therapy alone and improve clinical outcomes in the neoadjuvant setting.
- Other names
- Vandetanib and AnastrozoleZD6474 and AnastrozoleZD-6474 and AnastrozoleZD 6474 and Anastrozole
02
Targets
CYP19A1 (Aromatase)EGFR (Epidermal growth factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on vandetanib + anastrozole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vandetanib + anastrozole.